This suggests the potential for drug repositioning of the VEGF/VEGFR targeting agents from anti-angiogenic treatment in order to direct AML cell-targeting therapy, which is in concordance with previous experimental studies [17]. The gene discussed is VEGFA; the disease is acute myeloid leukemia.